Drugs / Nad-paclitaxel
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06056336 Background | Sep 2023 → Sep 2024 overdue | esophageal squamous cell carcinoma | Guo Xufeng | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nad-paclitaxel | “Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles.” NCT06056336 ↗ |